Role of N-acetylcysteine in adults with non-acetaminophen-induced acute liver failure in a center without the facility of liver transplantation. by Mumtaz, Khalid et al.
eCommons@AKU
Section of Gastroenterology Department of Medicine
December 2009
Role of N-acetylcysteine in adults with non-
acetaminophen-induced acute liver failure in a
center without the facility of liver transplantation.
Khalid Mumtaz
Aga Khan University, khalid.mumtaz@aku.edu
Zahid Azam
Aga Khan University, zahid.azam@aku.edu
Saeed Hamid
Aga Khan University, saeed.hamid@aku.edu
Shahab Abid
Aga Khan University, shahab.abid@aku.edu
Sadik Memon,
Aga Khan University
See next page for additional authors
Follow this and additional works at: http://ecommons.aku.edu/
pakistan_fhs_mc_med_gastroenterol
Part of the Gastroenterology Commons
Recommended Citation
Mumtaz, K., Azam, Z., Hamid, S., Abid, S., Memon,, S., Shah, S., Jafri, W. (2009). Role of N-acetylcysteine in adults with non-
acetaminophen-induced acute liver failure in a center without the facility of liver transplantation.. Hepatology international., 3(4),
563-70.
Available at: http://ecommons.aku.edu/pakistan_fhs_mc_med_gastroenterol/97
Authors
Khalid Mumtaz; Zahid Azam; Saeed Hamid; Shahab Abid; Sadik Memon,; Syed H Shah; and Wasim Jafri
This article is available at eCommons@AKU: http://ecommons.aku.edu/pakistan_fhs_mc_med_gastroenterol/97
ORIGINAL ARTICLE
Role of N-acetylcysteine in adults with non-acetaminophen-
induced acute liver failure in a center without the facility
of liver transplantation
Khalid Mumtaz Æ Zahid Azam Æ Saeed Hamid Æ
Shahab Abid Æ Sadik Memon Æ Hasnain Ali Shah Æ
Wasim Jafri
Received: 8 May 2009 / Revised: 20 July 2009 / Accepted: 17 August 2009 / Published online: 29 August 2009
 Asian Pacific Association for the Study of the Liver 2009
Abstract
Purpose We aimed to study the role of N-acetylcysteine
(NAC) in non-acetaminophen-induced acute liver failure
(NAI-ALF).
Methods A total of 47 adult patients were prospectively
enrolled with NAI-ALF (group 1 or NAC group) and oral
NAC was given. The primary outcome was reduction in
mortality with the use of NAC in NAI-ALF. The secondary
outcomes were to evaluate safety of NAC and to assess
factors predicting mortality. We compared these results
with records of NAI-ALF patients admitted in our hospital
from 2000 to 2003 (n = 44) who were not given NAC
(group 2 or historical controls).
Results The two groups were comparable for the etiology
of ALF, prothrombin time (PT), alanine aminotransferase,
creatinine, albumin, etc. The mean age in group 1 was
27.7 ± 11.8 years and in group 2 37.5 ± 18.8 years (P =
0.004). Bilirubin was 20.63 ± 11.03 and 14.36 ± 8.90 mg/dl
in groups 1 and 2, respectively (P = 0.004). There were 8
(17%) and 1 (2.3%) pregnant ALF women with acute
hepatitis E virus (HEV) infection in groups 1 and 2,
respectively (P = 0.031). All patients were given sup-
portive care, including mechanical ventilation. A total of
34 (37.36%) patients survived; 22 (47%) in group 1 (NAC
group) and 12 (27%) in group 2 (controls) (P = 0.05). On
multivariable regression analysis, patients not given NAC
(odds ratio [OR] = 10.3, 95% confidence interval [CI] =
1.6–65.7), along with age older than 40 years (OR = 10.3,
95% CI = 2.0–52.5), PT more than 50 s (OR = 15.4, 95%
CI = 3.8–62.2), patients requiring mechanical ventilation
(OR = 20.1, 95% CI = 3.1–130.2), and interval between
jaundice and hepatic encephalopathy (OR = 5.0, 95%
CI = 1.3–19.1) were independent predictors of mortality.
Conclusions The use of NAC causes reduction in NAI-
ALF mortality and its use was safe.
Keywords Liver failure  Acute  Mortality 
Acetylcysteine  Prospective/retrospective studies 
Viral  Survival rate
Background
Acute liver failure (ALF) is a rare but severe, life-threat-
ening, multisystemic medical emergency. It is defined as
the rapid development of acute liver injury with impaired
synthetic function and encephalopathy in a person who
previously had a normal liver. O’Grady et al. [1, 2]
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classified ALF into hyperacute, acute, and subacute liver
failure on the basis of encephalopathy less than 7, 8–28,
and more than 28 days but less than 26 weeks, respec-
tively, from the onset of jaundice. Hyperacute and acute
ALF have better prognosis in terms of survival than that in
subacute liver failure.
The role of N-acetylcysteine (NAC), a glutathione pre-
cursor, in the treatment of acetaminophen-induced ALF is
well established [3]. NAC prevents toxicity by limiting the
formation and accumulation of N-acetyl-p-benzoquinone-
imine and acts as a glutathione substitute and enhances
nontoxic sulfate conjugation [4, 5]. Its anti-inflammatory,
antioxidant, inotropic, and vasodilating effects improve
microcirculatory blood flow and oxygen delivery to vital
organs [6, 7]. NAC has shown to improve cerebral perfusion
pressure in randomized controlled trail (RCT) conducted on
pigs with ALF [8]. NAC has been used successfully in
patients with acetaminophen-induced ALF within 24 h and
even when it was administered after 24 h of paracetamol
ingestion. Smilkstein et al. [9] and Harrison et al. [10]
suggested that in cases when NAC is used after 24 h, it is
helpful because of the antioxidant effect rather than its
antidote effect. Because of its multiple mechanisms of
action, NAC has also been used in small trials in non-acet-
aminophen-induced ALF (NAI-ALF) with variable results
[11, 12]. Liver transplantation has made significant impact
on survival of patients with ALF [13, 14]. This option is
available only in limited centers of developed countries and
better alternatives must be explored in developing and
underdeveloped world for the management of ALF where
transplant facility is not available. Outcome of ALF in terms
of survival is poor in patients with NAI-ALF without liver
transplant facility [15]. Recently, in a nonrandomized study,
NAC use was reported to be associated with survival ben-
efits in children with NAI-ALF [16].
We started administering NAC in patients with NAI-ALF
because of the evidence of obvious efficacy of NAC in
paracetamol-induced ALF and with some evidence of its
role in NAI-ALF in the absence of liver transplant facility in
our hospital. We used NAC in a non-RCT comparing his-
torical controls at the end of 2003 in our hospital because of
its multifactorial mode of action and a good safety profile.
The primary outcome of our study was to assess the
reduction in ALF-induced mortality with the use of NAC in
patients with NAI-ALF. The secondary outcomes were to
evaluate the safety of NAC and also finding the factors
predicting the survival in patients with NAI-ALF.
Patients and methods
This is a prospective study with historical controls of adult
patients with NAI-ALF admitted at Aga Khan University
Hospital, Section of Gastroenterology, from 2000 to 2007.
Our hospital database for ALF cases was introduced in
2000, and the records of ALF cases were collected from
this source for studying the demographic features and
outcomes of ALF for historical controls. The cases prior to
2000 were not retrievable because there is no specific ICD
code for ALF. We started administering NAC in our
patients with NAI-ALF from January 2004.
Overall 110 patients were admitted from 2000 to 2007,
and 19 were excluded because of different reasons
including viral ALF along with history of acetaminophen
intake (n = 6) or acute-on-chronic liver disease (n = 11);
in two cases, patients’ attendant refused to give consent for
NAC administration. The included patients were divided
into two study groups: group 1 (2004–2007) included
patients prospectively enrolled and treated with NAC
(n = 47) and group 2 (2000–2003) included patients not
treated with NAC (n = 44). Data were retrospectively
collected from the hospital’s ALF database and were
double-checked after reviewing the medical records. Fig-
ure 1 shows patients enrolment in the two treatment arms.
Forty-seven patients with NAI-ALF who were adminis-
tered NAC were prospectively enrolled from January 2004
till March 2007, whereas the historical control (group 2)
included 44 consecutive adult patients with NAI-ALF
admitted from January 2000 to December 2003.
ALF was defined as the rapid development of acute liver
injury with impaired synthetic function and encephalopa-
thy in a person who previously had a normal liver. After
informed written consent was obtained from next of kin,
the patients in group 1 were administered oral NAC at a
dose of 140 mg/kg, followed by 70 mg/kg, for a total of 17
doses, 4 h apart within 6 h of admission. All patients were
managed with the standard supportive care treatment,
which was similar throughout the study period in both the
study groups. The patients received treatment of and pre-
vention for the complications of ALF [17]. The treatment
mainly involved continuous intravenous dextrose admin-
istration to prevent hypoglycemia; broad-spectrum pro-
phylactic antimicrobials to prevent bacterial infections and
antifungals when indicated, and proton pump inhibitors for
stress-related ulcers. With the development of advanced
hepatic encephalopathy, intensive care was provided with
hemodynamic monitoring, fluid and electrolyte balance,
ventilatory support, and propofol sedation. Fresh frozen
plasma was given in only those cases in which patients had
spontaneous bleed or required an invasive procedure, such
as a central venous or arterial catheter, etc. Nasogastric
tube was inserted for feeding purpose in patients with
encephalopathy or for checking upper gastrointestinal (GI)
bleed whenever needed [17].
At the time of admission, blood samples of all the
patients were taken for the etiological diagnosis of ALF,
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including hepatitis B surface antigen (HBsAg), hepatitis B
core IgM (HBc-IgM), hepatitis A virus IgM (HAV-IgM),
and hepatitis E virus IgM (HEV-IgM), and serum samples
were also saved for further testing if the etiology was not
detected at these initial tests, which included antinuclear
antibody, liver kidney microsomal antibody, ceruloplas-
min, HSV antibody, and EBV. Hepatitis D antibody was
sent for testing if HBsAg or HBc-IgM was positive to
detect HDV super- or coinfection as an etiology of ALF.
History was also noted for any hepatotoxic drug intake,
including homeopathic and herbal medications; pregnancy
was checked in female patients of childbearing age with the
help of b-HCG level and, later on, an ultrasound was also
performed.
Renal impairment was defined as serum creatinine level
of more than 2.0 mg/dl. Hemodialysis was performed
whenever indicated. Intracranial hypertension was diag-
nosed clinically in the presence of clinical signs such as
abnormal papillary reflexes or hypertonia. The intracranial
bolts were not inserted to measure the intracranial pressure
(ICP) in all these patients because it was not approved by
our hospital ethics review committee (ERC). Intracranial
hypertension was treated with mannitol and/or acute short-
term hyperventilation, but if the patient was refractory to
treatment, mild-moderate hypothermia was used with a
cooling blanket [18]. Infection was diagnosed only when
blood, urine, or tracheal aspirates were cultured for path-
ogenic microorganisms.
Primary outcome measure was an overall survival with
NAC as compared with standard supportive treatment in
the absence of the liver transplantation. Secondary outcome
measure was to evaluate the factors related to the survival
and safety of NAC in patients with NAI-ALF. A formal
approval of this study was taken from our hospital ERC
before the collection of data and assigning the patients for
receiving NAC.
Statistical analysis
Patients were analyzed in the two groups. Frequency dis-
tribution was assessed in terms of means ± 1 SD for
quantitative variables and number (percentages) for cate-
gorical variables. In univariate analysis, the categorical
variables were compared in the two groups by using v2 test
or Fisher exact test where appropriate. For continuous
variables, the independent sample t test was used to com-
pare the means in the two groups.
Multiple parameters were compared in survivors and
nonsurvivors in a univariate analysis. The factors on uni-
variate analysis with P \ 0.25 or any biological significant
factors were entered into a stepwise logistic regression
analysis to identify independent variables of prognosis. In
the multivariable logistic regression analysis, factors with
P \ 0.05 were taken significant to be in the final model.
All the analyses were performed by the Statistical
Package for Social Sciences (SPSS; Release 13, standard
version, copyright SPSS; 2004).
The study sample size was calculated considering the
mortality in NAI-ALF without liver transplantation ranges
from 74% to 88% and hence we took mortality with sup-
portive care as 84% (historical control group). For the NAC
group, the mortality was taken as 57% as reported in pre-
vious NAI-ALF trial using NAC [11]; with 5% level of
significance and 80% study power, the sample size calcu-
lated was 44 patients in each arm. All P values were two
sided.
Excluded 
n = 11 
Viral + Acetaminophen = 3 
Consent refusal = 2 
ACLF = 6 
Enrolled  
n = 47 
Enrolled 
 n = 44 
Survived 
n = 22 (47%) 
Died 
n = 25 (53%) 
Survived 
n = 12 (27%) 
  Group 1  
n = 58                    
(NAC group) 
  Group 2 
 n = 52      
 (Control/ No NAC group)  
NAI-ALF Screened 
n =110 
Excluded  
n = 8 
Viral + Acetaminophen = 3 
ACLF = 5 
 
Died 
n = 32 (73%) 
Fig. 1 Study enrolment
algorithm. NAC
N-acetylcysteine, ACLF acute
on chronic liver failure;
NAI-ALF non-acetaminophen-
induced acute liver failure
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Results
There were 47 patients in group 1 (NAC group) and 44 in
group 2 (historical control group). The mean age of
patients in group 1 was 27.7 ± 11.8 years and in group 2
37.5 ± 18.8 years (P = 0.004). Bilirubin level at the time
of admission was 20.6 ± 11.0 mg/dl versus 14.3 ± 8.9
mg/dl (P = 0.004). The other features such as serum
albumin, alanine aminotransferase, and creatinine levels,
ascites, gender distribution, and the interval between
jaundice and development of encephalopathy were similar
in the two groups, but there were more pregnant women in
group 1 that received NAC than in group 2. The baseline
characteristics are shown in Table 1.
We categorized the parameters according to the variable
used in the King’s College Hospital (KCH) criteria
(n = 10) in the two study groups as shown in Table 2.
There were 24 (51%) patients with bilirubin levels of more
than 17.6 mg/dl in group 1 versus 11 (25%) in group 2
(P = 0.011). Similarly, there were 42 (89.3%) patients in
group 1 younger than 40 years as compared with 28
(63.6%) in group 2 (P = 0.004). The interval between
jaundice and development of hepatic encephalopathy (B7
or [7 days) and prothrombin time (PT, in seconds) were
similar in the two groups (Table 2).
Majority of patients in both the group had ALF due to
acute HEV infection; 24 (51%) patients in group 1 and 16
(37%) in group 2 had ALF due to acute HEV infection
(P = 0.186). Of these HEV-infected patients, 8 (17%)
were pregnant women in group 1 and 1 (2.3%) in group 2
(P = 0.03; Fisher exact test). There were 11 (23.4%) and
14 (31.8%) acute HBV-related ALF cases in groups 1 and
2, respectively. Of these acute HBV (HBc-IgM positive)
patients, 3 (6.4%) patients in group 1 and 2 (4.5%) patients
in group 2 tested positive for HDV and were categorized as
having HDV coinfected ALF. There were no patients with
HDV superinfection (defined as HDV antibody-positive
patients with HBc-IgM negative and HBsAg positive) in
group 1, and there were 6 patients with HDV superinfec-
tion in group 2. There were 3 (6.4%) patients in group 1
and 8 (18.2%) in group 2 (P = 0.084) who had ALF
induced by antituberculosis treatment (including rifampi-
cin, isoniazid, and/or pyrazinamide). The etiology of ALF
in two groups is elaborated in Table 3.
A total of 56 (61.5%) patients were shifted to intensive
care unit; of these, 52 (57.1%) patients required ventilator
support, 36 (76.6%) belonged to group 1, and 16 (36.4%) in
group 2 (P \ 0.001). The mean number of days of admission
in hospital in group 1 was 9.4 ± 7.26 versus 8.39 ± 9.55 in
group 2 (P = 0.56).
Other supportive treatment given in the two groups is
shown in Table 4. Complications noted during hospital
course included different infections in 25 (53.2%) patients
in group 1 versus 22 (50%) patients in group 2 (P = 0.761).
A positive blood culture and sensitivity (C/S) result was
reported in 5 (10.6%) patients versus 6 (13.6%) patients
(P = 0.209); urine C/S in 9 (20.5%) versus 12 (25.5) in
groups 1 and 2, respectively (P = 0.561), and tracheal
aspirate C/S grew organisms in 21 (44.7%) in group 1
versus 13 (29.5%) in group 2 (P = 0.136). The renal
impairment was observed in 18 (40.9%) patients in group 1
versus 17 (36.2%) patients in group 2 (P = 0.642); signs of
Table 1 Baseline characteristics of study subjects in the two treatment groups
Characteristics N-Acetylcysteine
group (group 1, n = 47)
Control group
(group 2, n = 44)
P
Male gender 26 (55.3%) 24 (54.5%) 0.941
Age (years) 27.74 ± 11.79 37.52 ± 18.82 0.004
Prothrombin time (s) 59.55 ± 36.07 53.05 ± 30.57 0.357
Bilirubin (mg/dl) 20.63 ± 11.03 14.36 ± 8.90 0.004
Serum albumin (mg/dl) 2.73 ± 0.55 2.70 ± 0.75 0.820
Alanine aminotransferase (mg/dl) 1926 ± 1374.2 1457.2 ± 1467.8 0.342
Interval between jaundice and hepatitis E (days) 8.87 ± 9.47 13 ± 18.24 0.175
Creatinine at admission (mg/dl) 1.39 ± 0.82 1.57 ± 0.90 0.312
Presence of ascites 10 (21.3%) 16 (36.4%) 0.111
Pregnancy with acute hepatitis E 8 (17%) 1 (2.3%) 0.031a
Hepatic encephalopathy
Grade I 6 (12.8%) 6 (13.6%)
Grade II 9 (19.1%) 18 (40.9%) 0.128
Grade III 15 (31.9%) 9 (20.5%)
Grade IV 17 (36.2%) 11 (25.0%)
a Fisher exact test
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raised ICP, that is, dilated or unequal papillary reaction,
were observed in 24 (51.1%) and 15 (34%) patients in
groups 1 and 2, respectively. Thirty-five (74.5%) patients in
group 1 and 14 (31.8%) patients in group 2 were hyper-
ventilated to decrease their intracranial hypertension; 10
(21.3%) patients were subjected to cooling blanket in group
1 versus 4 (9.1%) patients in group 2 (P = 0.107). Mannitol
was used for signs of raised ICP at some stage during the
hospital course in 43 (91.5%) patients and 24 (54.5%)
patients in groups 1 and 2, respectively (P \ 0.001); sei-
zures were observed in 27 (57.4%) patients in group 1
versus 10 (22.7%) patients in group 2 (P \ 0.001); minor
GI bleeding (defined as coffee ground aspirate in nasogas-
tric tube without any hemodynamic change) in 18 (38.3%)
patients in group 1 versus 8 (18.2%) patients in group 2
(P = 0.034).
A total of 57 of 91 (62.6%) patients died with ALF
complications; 25 (53.2%) patients belonged to group 1
and 32 (72.7%) patients to group 2 (P = 0.05). A com-
parison of overall survival and length of hospital stay in the
two groups is shown in Fig. 2. It suggested a statistically
significant survival of patients in the group receiving NAC.
The causes of death were sepsis/multiorgan failure in 12
(54.5%) patients versus 22 (75.9%) patients in groups 1 and
2; raised ICP in 7 (31.8%) patients versus 6 (20.7%)
patients.
In the univariate analysis for the mortality in patients
with NAI-ALF, age older than 40 years, male gender, GI
bleeding during hospital course, development of ascites,
PT more than 50 s, infections, use of mannitol, seizures
during hospital stay, not using NAC, patients on mechan-
ical ventilator, and the interval between jaundice and onset
of hepatic encephalopathy of more than 7 days were sig-
nificant factors (P \ 0.25). These factors were taken for
stepwise multiple variable logistic regression analysis to
predict the factors responsible for the outcome variables of
mortality in the two groups. In the final model, age older
than 40 years, PT more than 50 s, not using NAC, patients
on mechanical ventilator, and the duration between jaun-
dice and onset of hepatic encephalopathy of more than
Table 2 King’s College Hospital prognostic criteria-related factors in the two groups
Characteristics N-Acetylcysteine group
(group 1; n = 47)
Control group
(group 2; n = 44)
P
Prothrombin time (s)
\50 23 (48.9%) 25 (56.8%)
[50 24 (51.1%) 19 (43.2%) 0.452
Bilirubin (mg/dl)
B17.6 23 (48.9%) 33 (75%)
[17.6 24 (51.1%) 11 (25%) 0.011
Age (years)
B40 42 (89.36%) 28 (63.63%)
[40 5 (10.64%) 16 (36.37%) 0.004
Interval between jaundice and hepatitis E (days)
B7 30 (63.8%) 24 (54.5%)
[7 17 (36.2%) 20 (45.5%) 0.368
Table 3 Etiology of ALF in the two treatment groups
Characteristics N-Acetylcysteine
(group 1; n = 47)
Control group
(group 2; n = 44)
P
Acute hepatitis A (HAV-IgM ?ve) 2 (4.3%) 0 (0%) 0.495a
Acute HBV (HBc-IgM ?ve) 11 (23.4%) 14 (31.8%) 0.369
HDV coinfection 3 (6.4%) 2 (4.5%) 1.000a
HDV superinfection 6 (4.5%) 0 (0%) 0.026a
Acute hepatitis E (HEV-IgM ?ve) 24 (51.1%) 16 (37.2%) 0.186
Drug-induced ALF (ATT, but not acetaminophen) 3 (6.4%) 8 (18.2%) 0.084
Acute fatty liver of pregnancy 0 (0%) 2 (4.5%) 0.264
Undetermined etiology 1 (2.1%) 4 (9.1%) 0.193a
a Fisher’s exact test
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7 days were the independent prognostic factors predicting
mortality in our study. The odds ratio and 95% confidence
interval of the final model are shown in Table 5.
Safety of NAC
NAC was administered orally in 47 patients in this study.
Adverse effects were noted in 6 (12.7%) patients within 4 h
after NAC administration. These were nonspecific macu-
lopapular rash in 2 patients, which resolved without any
treatment within 24 h; 1 patient had transient broncho-
spasm, which responded to salbutamol nebulization; and 4
patients had vomiting, which was attributed to the deteri-
orating condition due to ALF.
Discussion
There are limited data addressing NAI-ALF and the use of
NAC. Moreover, there is no reported RCT at the moment
checking the efficacy of NAC against placebo in these
patients. In this report of 91 patients with NAI-ALF
admitted to a center without the facility of liver trans-
plantation, we found that NAC administration was effec-
tive in reducing mortality in 47 patients as compared with
41 historical controls. We also found that the use of NAC
was safe in these patients. The two groups were compa-
rable in majority of clinical and biochemical parameters,
except that the patients in NAC group, on the one hand,
were younger, but, on the other hand, they had worse
prognostic factors at their baseline and even then their
survival was better. The main etiology of ALF was acute
hepatitis E followed by acute hepatitis B, and they were
equally distributed in the two groups of patients, although
there were more pregnant HEV patients in the NAC group.
Acute HEV infection is seen commonly in the third-world
country where waterborne infections are common. Khuroo
et al. [19] also reported HEV as the most common etiology
in patients with ALF from Kashmir, India.
Distribution of different complications of ALF, such as
renal impairment, and development of ascites and infec-
tions were similar in the two groups. There were signifi-
cantly more patients with raised ICP in group 1 (NAC
group) than in historical control. There were more patients
needing mechanical ventilation (78%) in the NAC group
due to raised ICP manifested by seizures, variable pupillary
reactions, and hyperventilation. There is a possibility that
the raised ICP was picked up earlier in the NAC group
patients who were admitted from 2004 to 2007 in the
hospital because of the improvement in the understanding
of the disease.
In ALF, oxygen supply and utilization are impaired by
changes in vascular tone at the cellular level. The use of
Table 4 Hospital course of non-acetaminophen-induced ALF in the two groups
Characteristics N-Acetylcysteine
(group 1; n = 47)
Control group
(group 2; n = 44)
P
Renal failure 9 (19.1%) 11 (25%) 0.50
Development of ascites 10 (21.3%) 17 (38.6%) 0.071
Mechanical ventilation 36 (76.6%) 16 (36.4%) \0.001
Infections 25 (53.2%) 22 (50%) 0.761
Features of raised intracranial pressure
Dilated/unequal pupils 24 (51.1%) 15 (34.1%) 0.102
Seizures activity 27 (57.4%) 10 (2.7%) \0.001
Use of mannitol 43 (91.5%) 24 (54.5%) \0.001
Hyperventilation 35 (74.5%) 14 (31.8%) \0.001
Cooling blanket 10 (21.3%) 4 (9.1%) 0.107
6050403020100
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Fig. 2 Survival and length of hospital stay in the two groups.
* P = 0.06 (Log-Rank test)
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NAC has been shown to increase oxygen utilization in the
microcirculation [20]. NAC may act by enhancing the
effect of nitric oxide on guanylate cyclase, increasing the
formation of cyclic 30,50-guanosine monophosphate, and
thereby resulting in vasodilatation.
In our study, on the one hand, most patients in the NAC
group were younger, but, on the other hand, they had poor
prognostic indicators of high bilirubin, HEV with preg-
nancy [21], and signs of raised ICP needing ventilation,
suggesting their critical condition. When we compared our
predictors of mortality with KCH criteria for NAI-ALF
[22], they were similar except that in our model, high
bilirubin level was not a predictor of mortality and not
using NAC was a predictor of mortality. The predictors of
mortality were similar to those from the study of Khuroo
et al. [19] in a setting without the facility of liver trans-
plantation. In our study, the mortality has decreased to 53%
with the use of NAC versus 73% in historical control group
(P = 0.05); similarly, Khuroo et al. [19] reported mortality
without liver transplantation in their study at 72.8%, in
which only supportive treatment was offered, which was
comparable with our control group, in which only sup-
portive treatment was offered.
One recently published study of NAC use in NAI-ALF
in children [16] reported that its use was associated with a
shorter length of hospital stay, in which survival with
native liver occurred in 22% with supportive care versus
43% with NAC and its use was associated with higher
incidence of native liver recovery without transplantation.
The results of this study are comparable with our results, in
which the survival in the supportive care group was 27%
versus 47% in the NAC group.
Strength and limitations of the study
The study has the potential to be clinically relevant because
our site has no liver transplant options, so it gives a proper
picture of the results of changing/adding a new therapy. In
patients with ALF, especially those in a center without
access to liver transplantation or for patients who are
inappropriate candidates for liver transplantation, mortality
is extremely high; therefore, showing a mortality benefit
with the use of NAC would be useful, given the relatively
low cost and minimal reported adverse effects of this
medication. Because NAC has had many proposed effects
on liver metabolism, showing efficacy in NAI-ALF may
help elucidate its true mechanism of action.
The main shortcoming of our study is its design, that is,
prospective study with historical control, which is intrin-
sically flawed in that the groups being compared are not
treated at same time in point. Advances have been made
from 2000 to 2007 in the management of acutely ill
patients, such as improved strategies for infection control,
better use of early goal-directed therapy, and better venti-
lator management strategies. Patients in the historical
control cohort may not have had access to benefit from
these advances as the intervention cohort (NAC group),
which would leave the historical control cohort (no NAC
group) disadvantaged in achieving good outcomes.
Although the two groups were not comparable, the data
suggest that group 1 had more severe disease than group 2.
NAC group has sicker patients as evidenced by the fact that
there were more pregnant HEV patients, much higher bil-
irubin levels, and higher incidence of raised ICP and PT in
them. Nevertheless, non-NAC group was considerably
Table 5 Independent risk
factor for mortality in patients
with non-acetaminophen-
induced ALF
a Reference category
FHF fulminant hepatic failure
Factors Adjusted odds
ratio
95% confidence interval
for adjusted odds ratio
Wald P
Age (years)
B40a
[40 10.3 2.0–52.3 0.005
N-Acetylcysteine
Givena
Not given 10.3 1.6–65.7 0.014
Type of FHF
Hyperacute liver failurea
Acute liver failure 5.03 3.1–130.3 0.018
Prothrombin time group (s)
B50a
[50 15.6 3.6–67.9 \0.001
Requirement of ventilator
Not ventilateda
Ventilated 20.1 3.1–130.2 0.002
Hepatol Int (2009) 3:563–570 569
123
older and worse outcomes happen with older patients.
Because of these limitations, we tried to control the con-
founders with multivariable regression analysis.
To our knowledge, two RCTs of NAC in NAI-ALF are
underway, one at the University of Pittsburgh and other at
KCH, London, and their results will be interesting in the
light of our report. It seems that NAC may be beneficial in
NAI-ALF, and until the results of the ongoing RCT are
available, we may continue to use NAC in patients with
NAI-ALF, particularly in centers without the facility of
liver transplantation because it was found safe and
decreased mortality.
Conclusions
Our results showed that NAC use is associated with a
reduction in NAI-ALF mortality and was safe to use. The
factors predicting mortality in NAI-ALF without liver
transplantation were age older than 40 years, PT more than
50 s, requirement of mechanical ventilator, not using NAC,
and the interval between jaundice and development of
HEV infection of more than 7 days.
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